These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. New monoclonal antibodies in renal transplantation. Vincenti F Minerva Urol Nefrol; 2003 Mar; 55(1):57-66. PubMed ID: 12773967 [TBL] [Abstract][Full Text] [Related]
5. Mechanistic considerations for the use of monoclonal antibodies for cancer therapy. Glassman PM; Balthasar JP Cancer Biol Med; 2014 Mar; 11(1):20-33. PubMed ID: 24738036 [TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults. Rao AV; Schmader K Am J Geriatr Pharmacother; 2007 Sep; 5(3):247-62. PubMed ID: 17996665 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers. Paci A; Desnoyer A; Delahousse J; Blondel L; Maritaz C; Chaput N; Mir O; Broutin S Eur J Cancer; 2020 Mar; 128():107-118. PubMed ID: 32037061 [TBL] [Abstract][Full Text] [Related]
8. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. Robak T; Robak E BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841 [TBL] [Abstract][Full Text] [Related]
9. Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development. Mascelli MA; Zhou H; Sweet R; Getsy J; Davis HM; Graham M; Abernethy D J Clin Pharmacol; 2007 May; 47(5):553-65. PubMed ID: 17379759 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and Pharmacodynamic Considerations for the Use of Monoclonal Antibodies in the Treatment of Bacterial Infections. Wang-Lin SX; Balthasar JP Antibodies (Basel); 2018 Jan; 7(1):. PubMed ID: 31544858 [TBL] [Abstract][Full Text] [Related]
11. Mechanisms of monoclonal antibody-drug interactions. Zhou H; Mascelli MA Annu Rev Pharmacol Toxicol; 2011; 51():359-72. PubMed ID: 20936946 [TBL] [Abstract][Full Text] [Related]
13. Development trends for human monoclonal antibody therapeutics. Nelson AL; Dhimolea E; Reichert JM Nat Rev Drug Discov; 2010 Oct; 9(10):767-74. PubMed ID: 20811384 [TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibody treatments for multiple sclerosis. Rose JW; Foley J; Carlson N Curr Neurol Neurosci Rep; 2008 Sep; 8(5):419-26. PubMed ID: 18713579 [TBL] [Abstract][Full Text] [Related]
16. Not your usual drug-drug interactions: Monoclonal antibody-based therapeutics may interact with antiseizure medications. Berman E; Noyman I; Medvedovsky M; Ekstein D; Eyal S Epilepsia; 2022 Feb; 63(2):271-289. PubMed ID: 34967010 [TBL] [Abstract][Full Text] [Related]
17. Induction immunotherapy with IL-2Ra monoclonal antibody in kidney transplantation. Ahsan N Minerva Urol Nefrol; 2003 Mar; 55(1):67-79. PubMed ID: 12773968 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Dostalek M; Gardner I; Gurbaxani BM; Rose RH; Chetty M Clin Pharmacokinet; 2013 Feb; 52(2):83-124. PubMed ID: 23299465 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic monoclonal antibodies: trends in development and approval in the US. Reichert JM Curr Opin Mol Ther; 2002 Apr; 4(2):110-8. PubMed ID: 12044031 [TBL] [Abstract][Full Text] [Related]